Telmisartan, ramipril, or both in patients at high risk for vascular events.

By S. Yusuf, K. Teo, Janice Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, C. Anderson. New England Journal of Medicine, 2008

3,508 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes (2016, background): “If one class is not tolerated, the other should be substituted (40) (C rating).”
Standards of Medical Care in Diabetes—2014 (2013, background): “However, such combinations have been found to provide no additional cardiovascular benefit and have higher adverse event rates (428).”
Standards of Medical Care in Diabetes—2013 (2012, background): “However, such combinations have been found to provide no additional cardiovascular benefit and have higher adverse event rates (353), and their effects on major renal outcomes have not yet been proven.”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “The combination of ACE-I and ARB is not recommended.(452) Specific benefits of such”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “The combination of ACE-I and ARB is not recommended.(452) Specific benefits of such”